MINERALYS THERAPEUTICS INC (MLYS) Stock Analyst Ratings
USA - NASDAQ:MLYS - US6031701013 - Common Stock
37.29 USD
-2.36 (-5.95%)
ChartMill assigns a Buy % Consensus number of 84% to MLYS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 44.63. This target is 19.67% above the current price.
MLYS was analyzed by 15 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about MLYS.
In the previous month the buy percentage consensus was at a similar level.
MLYS was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | Jefferies | Maintains | Hold -> Hold |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-11 | Jefferies | Initiate | Hold |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-13 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-10 | HC Wainwright & Co. | Initiate | Buy |
| 2024-04-02 | Goldman Sachs | Initiate | Buy |
| 2023-08-08 | Credit Suisse | Maintains | Outperform -> Outperform |
| 2023-05-16 | Credit Suisse | Reiterate | Outperform -> Outperform |
| 2023-03-16 | Credit Suisse | Maintains | Outperform |
| 2023-03-07 | Guggenheim | Initiate | Buy |
| 2023-03-07 | Stifel | Initiate | Buy |
| 2023-03-07 | Wells Fargo | Initiate | Overweight |
| 2023-03-07 | Evercore ISI Group | Initiate | Outperform |
| 2023-03-07 | Credit Suisse | Initiate | Outperform |
| 2023-03-07 | B of A Securities | Initiate | Buy |
MINERALYS THERAPEUTICS INC / MLYS FAQ
Can you provide the average price target for MINERALYS THERAPEUTICS INC stock?
15 analysts have analysed MLYS and the average price target is 44.63 USD. This implies a price increase of 19.67% is expected in the next year compared to the current price of 37.29.
How do analysts rate MINERALYS THERAPEUTICS INC (MLYS)?
The consensus rating for MINERALYS THERAPEUTICS INC (MLYS) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for MLYS stock?
The number of analysts covering MINERALYS THERAPEUTICS INC (MLYS) is 15.